Get the Stockscreener App
7.295
1.32%
0.095
Ocular Therapeutix Inc stock is traded at $7.295, with a volume of 1.22M.
It is up +1.32% in the last 24 hours and down -28.41% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$7.20
Open:
$7.29
24h Volume:
1.22M
Relative Volume:
0.33
Market Cap:
$1.60B
Revenue:
$52.04M
Net Income/Loss:
$-290.50M
P/E Ratio:
-5.0113
EPS:
-1.4557
Net Cash Flow:
$-240.94M
1W Performance:
-2.86%
1M Performance:
-28.41%
6M Performance:
-18.13%
1Y Performance:
-38.88%
1-Day Range:
$7.23
$7.465
1-Week Range:
$7.07
$7.75
52-Week Range:
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA
Compare OCUL vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
7.295 | 1.60B | 52.04M | -290.50M | -240.94M | -1.4557 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-12-26 | Initiated | UBS | Buy |
| Sep-15-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Long term debt to total equity ratio of Ocular Therapeutix Inc – HAN:0OT - TradingView
Ocular Therapeutix CLO Todd Anderman sells $87,363 in company stock - Investing.com
Form 4 Ocular Therapeutix Inc: Todd Anderman (CLO) For: 8 October - Investing.com India
To cover vesting taxes, Ocular Therapeutix (OCUL) legal chief sold 11,984 shares. - Stock Titan
Ocular Therapeutix Initiated at Buy by UBS - Moomoo
UBS Initiates Coverage on Ocular Therapeutix With Buy Rating, $14 Price Target - Moomoo
UBS initiates Ocular Therapeutix stock with buy rating on Axpaxli potential - Investing.com Canada
UBS initiates Ocular Therapeutix stock with buy rating on Axpaxli potential - Investing.com
Total debt per share of Ocular Therapeutix Inc – HAN:0OT - TradingView
OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights - Stocktwits
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
15 new hires receive stock awards from Ocular Therapeutix - Stock Titan
Officer Todd Anderman proposes selling 11,984 shares of Ocular Therapeutix (OCUL). - Stock Titan
Form 4 Ocular Therapeutix Inc For: 6 October By Investing.com - Investing.com Nigeria
Ocular Therapeutix, Inc. (OCUL) Presents at Euretina 2026Slideshow (NASDAQ:OCUL) 2026-10-06 - Seeking Alpha
Ocular Therapeutix CDO Peter Kaiser sells $70,429 in stock - Investing.com
An automatic tax-related sale of 9,990 shares at Ocular Therapeutix (OCUL) was not discretionary. - Stock Titan
To cover taxes, Ocular Therapeutix (OCUL) officer Heier sold 10,869 shares under automatic instructions. - Stock Titan
After stock vesting, an officer proposes selling 9,990 Ocular Therapeutix (OCUL) shares. - Stock Titan
Officer Jeffrey S. Heier proposes selling 10,869 Ocular Therapeutix (Nasdaq: OCUL) shares. - Stock Titan
Ocular Therapeutix (NasdaqGM:OCUL) Stock Forecast & Analyst Predictions - Simply Wall Street
Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws Scrutiny - Yahoo Finance
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD - Yahoo Finance
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences - Yahoo Finance
A Phase 3 eye-treatment trial is set for an October results presentation - Stock Titan
Operating income of Ocular Therapeutix Inc – HAN:0OT - TradingView
RBC Capital reiterates Ocular Therapeutix stock rating on wAMD treatment potential - Investing.com Nigeria
ETFs Investing in Ocular Therapeutix Inc Stocks - TradingView
Ocular Therapeutix, Inc. (OCUL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Precision Trading with Ocular Therapeutix Inc. (OCUL) Risk Zones - Stock Traders Daily
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst? - AlphaStreet
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know - Yahoo Finance
Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst? - Yahoo Finance
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success - TradingView
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success - Yahoo Finance
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Exploring a 171% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
New Ocular Therapeutix Target Price Amid Support - TheStreet Pro
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Nine new hires receive stock awards at Ocular Therapeutix - Stock Titan
Ocular Therapeutix reports positive pre-NDA FDA meeting for AXPAXLI - Glance by Eyes On Eyecare
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD - Yahoo! Finance Canada
Ocular Therapeutix Plans to File Eye Disease Drug Marketing Application in Q4 - Yahoo Finance
Ocular Therapeutix (OCUL) Up 5.8% to $11.26, Testing Key Resistance at $11.82Insider Buying Alerts - careplusvn.com
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs - Yahoo Finance
Ocular Therapeutix (OCUL) COO sells shares to cover taxes - Stock Titan
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences - GlobeNewswire
Ocular Therapeutix Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences - Yahoo Finance
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences - Stock Titan
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ocular Therapeutix Inc Stock (OCUL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TODD ANDERMAN | Officer |
Oct 08 '26 |
Proposed Sale |
7.29 |
11,984 |
87,315 |
0 |
| JEFFREY S. HEIER | Officer |
Oct 02 '26 |
Proposed Sale |
7.05 |
10,869 |
76,639 |
0 |
| Kaiser Peter | Chief Development Officer |
Oct 02 '26 |
Sale |
7.05 |
9,990 |
70,430 |
254,388 |
| PETER KAZUO KAISER | Officer |
Oct 02 '26 |
Proposed Sale |
7.05 |
9,990 |
70,459 |
0 |
| Heier Jeffrey S. | Chief Scientific Officer |
Oct 02 '26 |
Sale |
7.05 |
10,869 |
76,626 |
307,457 |
| DONALD D NOTMAN JR. | Officer |
Aug 31 '26 |
Proposed Sale |
10.24 |
1,099 |
11,252 |
0 |
| Notman Donald | Chief Operating Officer |
Aug 31 '26 |
Sale |
10.24 |
1,099 |
11,254 |
366,529 |
| PRAVIN DUGEL | Officer |
Aug 24 '26 |
Proposed Sale |
10.77 |
21,649 |
233,186 |
0 |
| JEFFREY S. HEIER | Officer |
Aug 24 '26 |
Proposed Sale |
10.78 |
3,296 |
35,532 |
0 |
| PETER KAZUO KAISER | Officer |
Aug 24 '26 |
Proposed Sale |
10.77 |
3,035 |
32,702 |
0 |
1.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):